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Polyphenolic compounds are plant nutraceuticals showing a huge structural diversity, including chlorogenic acids, hydrolyzable
tannins, and flavonoids (flavonols, flavanones, flavan-3-ols, anthocyanidins, isoflavones, and flavones). Most of them occur as
glycosylated derivatives in plants and foods. In order to become bioactive at human body, these polyphenols must undergo
diverse intestinal transformations, due to the action of digestive enzymes, but also by the action of microbiota metabolism.
After elimination of sugar tailoring (generating the corresponding aglycons) and diverse hydroxyl moieties, as well as further
backbone reorganizations, the final absorbed compounds enter the portal vein circulation towards liver (where other enzymatic
transformations take place) and from there to other organs, including behind the digestive tract or via blood towards urine
excretion. During this transit along diverse tissues and organs, they are able to carry out strong antiviral, antibacterial, and
antiparasitic activities. This paper revises and discusses these antimicrobial activities of dietary polyphenols and their relevance for
human health, shedding light on the importance of polyphenols structure recognition by specific enzymes produced by intestinal
microbial taxa.
1. Bioavailability of Dietary Polyphenols
1.1. Structural Diversity. Flavonoids are very abundant 15C
secondary metabolites in plants, containing two aromatic
rings (connected by a heterocycle pyrone ring), which are
tailored with diverse hydroxyl moieties. Some are produced
at chloroplasts as defense against oxidative damage generated
during photosynthesis [1]; others are produced at the sexual
organs as defense against solar UV [2], at the root area
as attractants for bacterial and fungal symbionts [3], or as
defense against virus, bacteria, fungi, and herbivores [4].
All flavonoids derive from L-phenylalanine, due to
diverse transformations taking place at the phenylpropanoid
pathway. Initial common steps are conversion of L-Phe in
cinnamic acid (by phenyl ammonia lyase (PAL)), its con-
version in p-coumaric acid (by cinnamate-4-hydroxylase
(C4H)), and its transformation in p-coumaroyl-CoA (by 4-
coumaroyl-CoA ligase (4CL)) [5]. Both p-coumaric acid and
p-coumaroyl-CoA are building blocks for hydroxycinnamic
acids and flavonoids, respectively (Figure 1) [5].
In flavonoid biosynthesis, one molecule of p-coumaroyl-
CoA and three molecules of malonyl-CoA are used by the
chalcone synthase (CHS) in order to generate a bicyclic
chalcone as naringenin chalcone (Figure 1) [4]. Chalcones are
substrates for chalcone isomerase (CHI), which carries out
the B-ring closure at these compounds, rendering flavanones
(as naringenin from citrus fruits) (Figure 2). All flavonoid
subfamilies derive from these 15C flavanones (Figure 2
shows the atom numbering and ring denomination). Other
phenylpropanoid enzymes will generate diverse final prod-
ucts as shown in Figure 2 [4]. Flavone synthase (FNS)
will generate flavones (as apigenin from celery). Isoflavone
synthase (IFS) will generate isoflavones (as genistein from
soy). Flavanone-3-hydroxylase (F3H) will generate dihy-
droflavonols (as aromadendrin from pine trees). Flavonol
synthase (FLS) will generate flavonols (as quercetin from
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Figure 1: Initial common steps during hydroxycinnamic acids and flavonoids biosynthesis in plants.
onion or kaempferol from capers). Dihydroflavonol reduc-
tase (DFR) and anthocyanin synthase (ANS) will generate
anthocyanidins (as pelargonidin from diverse red flowers).
Anthocyanidin reductase (ANR) will generate flavan-3-ols
(as epicatechin from cocoa).
Flavonoids are usually present and stored in plant tissues
in the form of diverse derivatives, mostly as sugar O-conju-
gates at C2 (chalcones), at C3 (flavonols, anthocyanidins, and
flavan-3-ols), or at C7 (flavanones, flavones, and isoflavones)
positions.Most common bound sugars are glucose, galactose,
rhamnose, xylose, rutinose, arabinopyranose, and arabino-
furanose [6]. These modifications (and others as methyla-
tions and gallate tailoring) add extra structural stability to
flavonoids during storage in vacuoles and chloroplasts [7–9].
Once the plant, fruit, or seed is recollected, flavonoids usually
have good stability in this conjugated state and keep high
concentrations in food and beverages. All thesemodifications
in chemical structure and sugar binding will determine their
absorption and bioavailability [10–13].
1.2. Intestinal Absorption. The study of flavonoids metab-
olism in human body is crucial to determine which ones
are better absorbed and which ones lead to formation of
bioactive metabolites. Following the ingestion of flavonoids,
sugar moieties (as in quercetin-3-glucoside) are cleaved from
the phenolic backbone in the small intestine and absorbed
here. Enzymes as lactase phlorizin hydrolase (LPH) (at
enterocyte membrane) or 𝛽-glucosidase (CBG) (cytosolic,
for polar glycosides) hydrolyze glycosylated flavonoids and
then aglycones enter epithelial cells by passive diffusion [14–
16] (Figure 3). However, flavonoids linked to a rhamnose
moiety must reach the colon and be hydrolyzed by the 𝛼-
rhamnosidases secreted by the colon microbiota (as Bifi-
dobacterium dentium), in order to proceed to its absorp-
tion [17] (Figure 3). Flavan-3-ols, such as (−)-epicatechin,
are never glycosylated but often acylated by gallic acid.
These compounds are absorbed at enterocyte level without
any deconjugation or hydrolysis [18]. Proanthocyanidins are
polymers of high molecular weight, and therefore oligomers
larger than trimers are unlikely to be absorbed in the small
intestine in their native form [19].
The other main family of polyphenols, hydroxycinnamic
acids, are commonly esterified to sugars, organic acids, and
lipids. There are no esterases in human tissues able to break
these ester links, so the main site for its metabolism is
colonic microbiota, although up to one third of their absorp-
tion can also take place in the small intestine [46–49].
Some hydroxycinnamic acids, as ellagitannins, are polymers
(Figure 4). These are resistant to the action of LPH or
CBG and consequently cannot be absorbed in the small
intestine, reaching the colon, where its microbiota cleaves the
conjugating moieties. The resultant aglycones are extensively
metabolized by this microbiota, leading to the production of
various hydroxyphenylacetic acids [50, 51].
Once a final derivative or aglycon has been absorbed (at
small intestine or colon), it undergoes some degree of phase
II metabolism at enterocyte level, as methylation (at C3󸀠 or
C4󸀠 by catechol-O-methyltransferase (COMT)), sulfation (at
C3󸀠, C4󸀠, C5, or C7 by sulfotransferases (SULT)), and glu-
curonidation (by UDP-glucuronosyltransferases) (Figure 3).
Then these products enter the blood stream by the portal
vein, reaching the liver, where they may be subjected to
more phase II metabolism, hence becoming conjugated and
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Figure 2: Biosynthetic steps for generation of flavonoid subfamilies. Naringenin structure shows atom numbering and apigenin structure
shows rings denomination.
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Figure 4: Biosynthetic steps for generation of two hydroxycinnamic acid polymers: ellagitannins and gallotannins.
transported to the bloodstream again until they are secreted
in urine (Figure 3) [25, 52–61]. Some of the liver conjugates
are then excreted as bile components back into the intestine
(enterohepatic recirculation) and deconjugated compounds
are regenerated by gut microbial enzymes before being
reabsorbed again [21, 62, 63]. The unabsorbed metabolites
are eliminated via faeces (Figure 3). All these conjugation
mechanisms are highly efficient, and free aglycones are gen-
erally absent or present in low concentrations in plasma after
nutritional doses. An exception is green tea catechins, whose
aglycones constitute a significant proportion of the total
amount in plasma, as they are nonglycosylated flavonoids in
food and are readily absorbed at the small intestine without
extra modifications [12].
2. Antimicrobial Effects of
Dietary Polyphenols and Their Gut
Microbiota Metabolites
The level of biotransformations suffered by a specific dietary
polyphenol along the gastrointestinal tract is determined by
two main factors. One is the specific structural subfamily
of the polyphenol, as its scaffold will allow only some
transformations, to be carried out by intestinal enzymes and
gut microbiota species. This chemical structure will there-
fore, at this initial level, restrict the range of possible final
bioactive products to be absorbed and consequently the
scale of possible antimicrobial properties generated as a
result of these biotransformations on dietary polyphenols.
The second factor is the individual richness at the level of
intestinal microbiota, as some specific biotransformations on
dietary polyphenols can be carried out by a vast array of gut
microbial species and genera (as deglycosylations), but other
more specific chemical reactions on polyphenols require the
presence of particular species or strains gifted with special
genes coding for precise enzymes (as those responsible for
intestinal generation of urolithins or (S)-equol).
Along the next sections, intestinal transformations of
dietary polyphenols by diverse microbiota species (and the
antimicrobial bioactivities of those derivatives) are organized
according to their different structural subfamilies.
2.1. Flavonols. Flavonols (kaempferol, quercetin, andmyrice-
tin) (Figure 2) share the 3-hydroxyflavone backbone. Differ-
ent positions for the phenolic OH moieties give diversity to
this subgroup. They are found as glycosylates in many com-
mon foods as onion, capers, apples, broccoli, grapefruit, and
plums. One of the most important diet flavonols is quercetin,
whose 4󸀠-O-glucoside and 3,4󸀠-O-diglucoside, among others,
are abundant in onion and propolis, for example [64, 65].
The type of initial glycosylation pattern affects flavonols
degradation rates in the gut. Metabolism of di- and trisaccha-
rides is much slower compared to that of flavonol monosac-
charides. Position of the hydroxyl groups may also influence
their degradation, as recent studies indicate that flavonoids
without hydroxyl groups at the C5, C7, and C4󸀠 positions
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are degraded slower. Some gut microbiota species that have
been involved in this hydrolysis are Bacteroides distasonis,
Bacteroides uniformis, Bacteroides ovatus, Enterococcus cas-
seliflavus, and Eubacterium ramulus [20, 21, 66, 67]. Also, the
type of glycosidic bond (C- or O-glycosides) has influence
on their degradation rates. Metabolism of a C-glycosidic
bond seems to be much slower than the hydrolysis of an
O-glycosidic bond. This is of interest from a nutraceutical
point of view, as the slow degrading compounds may be
more bioavailable, because they have greater opportunity to
be absorbed than the ones that are degraded at a quicker rate
at colon level [66].
Once flavonols have been metabolized in their aglycones,
they are extensively degraded by other colonic microbiota,
generating simpler phenolic compounds derived from A-
and B-ring metabolism, after the flavonoid C-ring has been
broken down [64] (Table 1, Figure 5). C-ring breakdown
takes place at different positions (breaking the bond between
C1 and C2 positions, between C3 and C4, or between C4
and C10) giving rise to a high number of simple phenolics
(Table 1, Figure 5). Some gut microbiota involved in this C-
ring breakdown is Eubacterium oxidoreducens, E. ramulus, E.
casseliflavus,Clostridium orbiscidens, and others belonging to
Butyrivibrio genus [20–23].
Following the C-ring fission, dehydroxylation occurs
at the two remaining free phenolic rings (Figure 5). The
hydroxylation pattern of A- and B-ring affects therefore
the type of phenolic compounds produced, which will be
finally absorbed at colon level. For example, the primary
gut microbiota metabolites of quercetin are 2-(3,4-dihy-
droxyphenyl)-acetic acid (from A-ring) and protocatechuic
acid (from B-ring), and those ones of myricetin are 2-(3,5-
dihydroxyphenyl)-acetic acid (from A-ring) and gallic acid
(from B-ring) (Figure 5). Further dehydroxylation results in
the formation of 2-(3-hydroxyphenyl)-acetic acid from both
metabolites [22, 23, 68].
With respect to bioactivity, flavonols have been described
as antiviral, inhibiting HIV-1 integrase, although in a non-
specific way, but also against HSV, respiratory syncytial
virus, and poliovirus [69, 70]. Quercetin has been shown to
potentiate the action of acyclovir against HSV infection [71].
With respect to its antibacterial activity, oral administration
of quercetin protected against Shigella infection in an animal
model using a 140mg/kg doses [72]. Escherichia coli gyrase
is inhibited by quercetin and other flavonols, by inhibiting
the ATPase GyrB subunit [73]. In in vitro assays, quercetin
increases the bacterial cell membrane, giving rise to dissi-
pation in membrane potential, and diminished cell motility,
which is an important factor in bacterial virulence [74].
2.2. Flavanones. This class of flavonoids (hesperetin, narin-
genin) (Figure 2) has a 2,3-dihydro-2-phenylchromen-4-one
structure. They are very abundant in citrus fruits and toma-
toes. They seem to be more bioavailable than other close
flavonoids such as flavonols or flavan-3-ols. This can be due
to the fact that these compounds are less degraded by colonic
microbiota and therefore they are more available for absorp-
tion [24].The reason for this can be their commonpresence in
food as rutinosides (bound to the disaccharide rutinose: 6-O-
𝛼-L-rhamnosyl-D-glucose) and neohesperidosides (bound
to the disaccharide neohesperidose: 2-O-𝛼-L-rhamnosyl-D-
glucose), a tailoring that seems to be resistant to some colon
microbiota species. In both cases, these disaccharides are
attached at position C7. By contrast, flavanone glucosides are
rare.
Flavanones deglycosylation and further degradation by
colonic microbiota pathway is similar to that observed in
flavonols (Figure 5), with the main difference being C-ring
cleavage between C1 and C2 positions or between C4 and C10
ones. Clostridium species and E. ramulus are able to carry out
these transformations in the colon [21, 24].
The flavanone hesperetin aglycon (e.g., from citrus fruits)
shows a notable inhibitory activity against vancomycin-
intermediate Staphylococcus aureus (VISA) and against Heli-
cobacter pylori [75, 76]. It possesses also a synergistic effect
on VISA when combined with antibiotics like vancomycin
and oxacillin [75]. It inhibits also intracellular replication of
diverse virus (herpes simplex virus type-1, poliovirus type-1,
parainfluenza virus type-3, influenza A virus, and respiratory
syncytial virus) [77, 78].
Its glycosylated flavanone, hesperidin, shows antibacterial
activity against Aeromonas hydrophila, an emerging human
pathogen that causes both intestinal and extraintestinal
infections. In a murine model, hesperidin showed inhibition
of bacterial colonization and a significant increase in anti-
LPS IgM levels and reduction of anti-LPS and anti-ECP IgA
levels to their normal values [79]. Hesperidin also shows
activity against infection with human rotavirus [80] and
against influenza virus replication in vitro by inhibition of the
viral sialidase activity [81]. Growth of fungus Phytophthora
citrophthora has been inhibited in vitrowith this glycosylated
flavanone, suggesting its role as antifungal toxin in the fruits
of Citrus sinensis, a big source of this flavanone [82]. Also
antiparasitic activity of hesperidin in vitro and in vivo has
been shown against adult worms of Schistosomamansoni, the
causative agent of schistosomiasis [83].
Sulphonated hesperidin, one of its plasma metabolites,
inhibits pathogens like Chlamydia trachomatis and Neisseria
gonorrhoeae in vitro [84]. This conjugate also inhibits the
enveloped viruses herpes simplex virus type-2 and human
immunodeficiency virus (HIV) to the point that it has been
suggested as a contraceptive antimicrobial agent against HIV
transmission [84].
2.3. Flavan-3-Ols. Flavan-3-ols (Figure 2) form a very com-
plex group of flavonoids consisting of simple flavan-3-ols
(catechin and epicatechin; gallocatechin, epigallocatechin,
and the corresponding gallate esters) and their polymeric
forms. They are abundant in green tea, cocoa, kola, banana,
and pomegranate.
Such broad polymerization degree and galloylation deter-
mine their bioavailability, as oligomers with a degree of
polymerization>3 are not absorbed in the small intestine, and
therefore they are metabolized in the colon [19, 25]. Their
gallate esters are catabolised by colon microbiota, as, for
example, epicatechin gallate and epigallocatechin gallate,
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Table 1: Main metabolites derived from flavonoids and identified bacteria involved in their transformation.
Precursors Main metabolites identified Bacteria References
Kaempferol 2-(4-Hydroxyphenyl)propionic acid Clostridium orbiscidens [20]
Flavonols Quercetin
2-(3,4-Dihydroxyphenyl)acetic acid
2-(3-Hydroxyphenyl)acetic acid
3-(3,4-Dihydroxyphenyl)propionic acid
3-(3-Hydroxyphenyl)propionic acid
C. orbiscidens, Eubacterium
oxidoreducens
Eubacterium ramulus
Enterococcus casseliflavus
[21–23]
Myricetin 2-(3,5-Dihydroxyphenyl)acetic acid2-(3-Hydroxyphenyl)acetic acid C. orbiscidens, E. oxidoreducens [20, 22, 23]
Flavanones Naringenin 3-(4-Hydroxyphenyl)propionic acid Clostridium strainsE. ramulus [21, 24]
Flavan-3-ols
Catechin
Epicatechin
3-(3-Hydroxyphenyl)propionic acid
5-(3󸀠,4󸀠-Dihydroxyphenyl)-𝛾-valerolactone
5-(3,4-Dihydroxyphenyl)valeric acid
3-(3,4-Dihydroxyphenyl)propionic acid
Clostridium coccoides, Bifidobacterium
spp. [25–28]
Epigallocatechin 5-(3
󸀠,4󸀠-Dihydroxyphenyl)-𝛾-valerolactone
5-(3󸀠,5󸀠-Dihydroxyphenyl)-𝛾-valerolactone
Anthocyanins
Cyanidin 3,4-Dihydroxybenzoic acid
Lactobacillus plantarum, Lactobacillus
casei, Lactobacillus acidophilus LA-5,
Bifidobacterium lactis BB-12
[29, 30]Peonidin 3-Methoxy4-hydroxybenzoic acid
Pelargonidin 4-Hydroxybenzoic acid
Malvidin 3,4-Dimethoxybenzoic acid
Isoflavones
Daidzein (S)-Equol
Bacteroides ovatus, Streptococcus
intermedius, Ruminococcus productus,
Eggerthella sp.Julong 732, Enterococcus
faecium EPI1, Lactobacillus mucosae EPI2,
Finegoldia magna EPI3
[31–33]
O-Demethylangolensin Clostridium spp. HGHA136 [34]
Genistein 6󸀠-Hydroxy-O-desmethylangolensin [35]
Formononetin Daidzein [36]
Biochanin A Genistein [36]
Flavones Luteolin,apigenin
3-(3,4-Dihydroxyphenyl)-propionic acid,
3-(4-hydroxyphenyl)-propionic acid,
3-(3-hydroxyphenyl)-propionic acid, and
4-hydroxycinnamic acid, phloretin
C. orbiscindens, Enterococcus avium [37]
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Figure 5: Colonic degradation of quercetin glycosides, as an example of flavonol glycosides.
generating aglycones and gallate, which is further decarboxy-
lated into pyrogallol [25, 26, 85].
Flavan-3-ols aglycones lack a carbonyl group at C4 (as
present in flavonols and flavanones). This may be the reason
to avoid its transformation by colonic microbiota which
modifies other types of flavonoids, as E. ramulus [27].
Once the initial gallate esters have been metabo-
lized, the aglycones suffer C-ring opening, giving rise to
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diphenylpropan-2-diol, which is further converted into 5-
(3󸀠,4󸀠-dihydroxyphenyl)-𝛾-valerolactone. This lactone ring
opens and gives rise to 5-(3,4-dihydroxyphenyl)valeric acid.
Further transformations generate OH-phenylpropionic and
hydroxy-benzoic acids [25, 27] (Figure 6) (Table 1). Bacteria
responsible for thesemetabolic reactions belong to the genera
Bifidobacterium (as Bifidobacterium infantis) andClostridium
(as Clostridium coccoides). Actually, colonic populations of
Bifidobacterium are increased in subjects consuming high
doses of flavan-3-ols [28], which further enhance the benefits
of flavan-3-ols consumption. These bacteria are resistant to
these compounds because they do not use heme-containing
enzymes, and these flavan-3-ols are important iron-chelating
compounds [86].
In recent years, several studies have reported that the
main catechin of green tea leaves, epigallocatechin-3-gallate
(EGCG), has anti-infective properties [87]. Inhibition effect
of EGCG on the capacity to infect cells by several viruses has
been reported by different authors, who found that EGCG
inhibits entry of hepatitis C virus by impairing virus binding
to the cell surface [88–90]. EGCG also shows antiviral effects
against HIV-1, interfering with several aspects of its life cycle.
It interacts with the viral envelope destroying viral particles
[91], prevents attachment of virions to cells downregulating
CD4 cell surface receptor expression [92, 93], affects viral
replication via inhibition of reverse transcription [94], and
inhibits proviral genome integration by binding between the
integrase and the viral DNA [95]. The antiviral activity of
EGCG against influenza virus infection in cell culture was
attributed to agglutination of virus particles thus preventing
virus from adsorbing to cells [96]. EGCG also inhibits
the acidification of endosomes and lysosomes required for
the fusion of viral and cellular membranes [97] as well as
of neuraminidase activity responsible for preventing self-
aggregation of virus particles [98]. Clinical studies performed
to investigate the preventive effect of catechins consumption
on influenza infection in humans found this statistically
significant [99, 100]. Enterovirus 71 [101], human hepatitis
B virus [102], adenovirus [103], Epstein-Barr virus [104],
and herpes simplex virus [105] are also clearly affected by
EGCG.
With regard to antibacterial activity, there are multiple
mechanisms by which EGCG exerts this activity against
Staphylococcus, including damage to the lipid bilayer of
the cell membrane [106], decrease slime production and
inhibition of biofilm formation [107], binding and neutral-
ization of enterotoxin B [108], and working with a synergistic
effect in combination with 𝛽-lactams [109] or carbapenems
[110]. Other bacteria killed by the action of EGCG are
Streptococcus pyogenes [111], Bacillus spp. and Clostridium
spp. [112], Salmonella typhi [113], and enterohemorrhagic E.
coli [114]. The general antibacterial property of flavan-3-ols
explaining these effects can be their chelating properties on
iron, an important oligoelement for heme-utilizing bacteria
[25]. EGCG inhibits growth of Legionella pneumophila inside
macrophages not by any direct antibacterial effect on the
pathogen, but due to selective changes in the immune
response of macrophages and enhanced production of
cytokines [115].
The antimicrobial effect of EGCG is also extended to
eukaryote microorganisms, as against Candida spp. and the
dermatophytes Cryptococcus neoformans and Trichophyton
mentagrophytes [116]. EGCG specifically inhibits the germi-
nation of T. mentagrophytes conidia and subsequent hyphal
growth [117]. These positive led to establishing in vivo
research with EGCG in a murine model of disseminated
candidiasis, showing its antifungal activity in vivo and its
synergistic effect when combined with amphotericin B [118].
EGCG inhibits epimastigotes growth of Trypanosoma
cruzi and increases mice survival rates in EGCG-treated
animals that point out to a potential new compound for
chemotherapy of Chagas disease [119]. EGCG also inhibits
37%–80% of binding of various isolates of Plasmodium
falciparum to the ICAM-1 cellular receptor related to cerebral
malaria [120]. The lethal mitochondrial damage that EGCG
causes to Leishmania donovani [121] and Leishmania ama-
zonensis [122] has been explained by its inhibition in the
enzymatic activity of the parasite arginases [123].
2.4. Anthocyanidins. Unlike other flavonoids that are
absorbed and secreted, anthocyanins, the glycosylated ver-
sions of anthocyanidin aglycons (as cyanidin, pelargonidin,
and malvidin), do not appear to undergo extensive metab-
olism of the parent glycosides to glucuronic, sulfo or
methyl derivatives, and therefore their bioavailability is very
low [24]. Procyanidins occur in monomeric as well as in
oligomeric and polymeric forms and are the most abundant
and bioactive dietary polyphenols, as they are responsible for
most red, blue, and purple color in fruits (specially berries),
flowers, and leaves, besides having an important antioxidant
activity [29, 30].
Since only a small part of ingested anthocyanins is
absorbed at small intestine, large amounts of these com-
pounds are likely to enter the colon, where they are deg-
lycosylated by gut microbiota [124]. The gut microbiota
has a high hydrolytic potential and ring scission properties
so several anthocyanins degradation products have been
identified. Some of them include vanillic, phloroglucinol, and
protocatechuic acid [124, 125]. For example, incubation of
malvidin-3-glucoside (from grape extracts) with fecal bac-
teria results in formation of gallic, syringic, and p-coumaric
acids (Figure 7) (Table 1). Some species responsible for this
degradation are Lactobacillus plantarum, Lactobacillus casei,
Lactobacillus acidophilus, and Bifidobacterium lactis [29, 30].
All the anthocyanins and their metabolites tested signifi-
cantly enhance growth of Bifidobacterium spp., Lactobacillus
spp., and Enterococcus spp. Therefore anthocyanins and their
metabolites could perform a positivemodulation of intestinal
bacterial populations [126].
There are different mechanisms that can explain the
antimicrobial activity of anthocyanins, as they can cause
localized disintegration of bacterial outer membrane, leaking
of cytoplasm (with the presence of significant amounts
of cytoplasmic material and membrane debris outside the
cells), and irregular shape [127]. The mechanisms thought
to be responsible for the toxicity of pure anthocyanidin
compounds to microorganisms include enzyme inhibition
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by the oxidized compounds, possibly through reaction with
sulfhydryl groups or through more nonspecific interactions
with proteins often leading to inactivation of the membrane
protein and loss of function. Probable targets in themicrobial
cell are surface-exposed adhesions, cell wall polypeptides,
and membrane-bound enzymes. Anthocyanidins may also
render substrates unavailable to microorganisms, as some
oligoelements [128, 129].
Many studies have shown the antimicrobial activities
of the crude extract, fractions, and pure anthocyanidins
from different berries. In bilberries (Vaccinium myrtillus),
anthocyanins comprise 90% of the phenolic compounds.
Extracts from bilberry and blueberry (Vaccinium corymbo-
sum) showed inhibitory effects on the growth of Gram-
positive bacteria (Listeria monocytogenes, S. aureus, Bacillus
subtilis, and Enterococcus faecalis) and Gram-negative ones
(Citrobacter freundii, E. coli, Pseudomonas aeruginosa, and
Salmonella enterica ser. Typhimurium). However yeasts are
resistant to these berry extracts [130].
Cyanidin-3-O-glucoside (C3G) inhibits the secretion of
both VacA and CagA, two key virulence factors of H. pylori
[131, 132]. C3G downregulates VacA secretion in H. pylori
via inhibition of SecA expression (a protein involved in
translocation of bacterial proteins out of the bacterial plasma
membrane), causing a decrease in apoptosis in H. pylori-
infected cells [132].
Cyanidin-3-sambubioside, a natural anthocyanin derived
from black elderberry extract, binds to influenza virus neu-
raminidase within the 430-cavity, acting as a potent inhibitor
of sialidase activity. This natural anthocyanin binds in the
vicinity of neuraminidase residues 356–364 and 395–432,
shielding proteases from releasing these peptide segments
from the active site. This binding mode has not been seen
with other influenza neuraminidase inhibitors so that the
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compound and its derivatives definitely offer the potential for
the development of a new class of antivirals against influenza
[133].
2.5. Isoflavones. Almost all isoflavones (daidzein, genistein,
and formononetin) exist as glucosides and therefore are
not absorbed across enterocytes due to their high polarity
and molecular weight. These flavonoids are present almost
exclusively in plants from the Fabaceae family (soy, lentils,
beans, and chickpeas).Their bioavailability requires therefore
conversion of glucosides into the bioactive aglycones via the
action of intestinal 𝛽-glucosidases from small intestine bac-
teria (Lactobacillus, Bifidobacterium). Then, these aglycones
are uptaken to the peripheral circulation [134].
One of the most active isoflavones, daidzein, is metab-
olized in two different ways depending on subjects and
their gut microbiota. Some subjects produce (S)-equol via
dihydrodaidzein and tetrahydrodaidzein (resulting from the
activities of Streptococcus intermedius, B. ovatus, Ruminococ-
cus productus, Lactobacillus mucosae EPI2, E. faecium EPI1,
Veillonella spp., Eggerthella sp. Julong732, and Finegoldia
magna EPI3) [31–33] (Figure 8). However others pro-
duce O-desmethylangolensin (O-DMA) via 2󸀠-dehydro-O-
demethylangolensin (generated by Clostridium spp.) [34]
(Figure 8) (Table 1). Therefore, there are two groups of sub-
jects, (S)-equol producers and nonproducers. The inability
to produce (S)-equol is a consequence of the lack of specific
components in the intestinal microbiota, as the species
described before. (S)-equol shows high antioxidant activity
due to its nonplanar structure, which enables it to penetrate
more easily into the interior of the cell membrane, preventing
oxidative damage in situ. Also its estrogenic activity on
mammal cells is higher in comparison with other phy-
toestrogens. This compound binds to estrogen receptor in
mammal cells, downregulating its activity. This may have
potential application in breast and prostate cancer therapy
and prevention [135–137]. In addition to (S)-equol and O-
DMA, other less activemicrobialmetabolites of daidzein have
been reported [138].
Microbial metabolism of isoflavone genistein is different
from that of daidzein. Genistein is reduced to dihydro-
genistein, which is further metabolized to 6󸀠-hydroxy-O-
desmethylangolensin [35].
Other less common isoflavones found in red clover
are formononetin and biochanin A, which are converted
in a similar way to microbial metabolites. Formononetin
is rapidly converted via daidzein to O-DMA and (S)-equol.
Biochanin A is metabolized via genistein to 6󸀠-hydroxy-O-
desmethylangolensin [36]. Then, all these isoflavone agly-
cones are further transformed by C-ring cleavage and dehy-
droxylation reactions in the colon.
Apart from their estrogenic activity, studies with respect
to the antimicrobial activity of isoflavones have been de-
scribed, as, for example, inhibition of S. aureusMRSA strains
at concentrations over 128 𝜇g/mL [139–141]. These activities
are thought to be due to inhibition of bacterial topoisomerase
IV [142].
2.6. Flavones. These flavonoids (luteolin, apigenin) share
the 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one)
backbone.They are present in food as cereals, parsley, thyme,
celery, and citrus fruits. Once the corresponding glucosides
have been hydrolyzed at intestinal level, unabsorbed aglycons
are furthermetabolized by colonmicrobiota (C. orbiscindens,
Enterococcus avium), breaking down their C-ring towards
phloretin chalcone, 3-(3,4-dihydroxyphenyl)-propionic acid,
3-(4-hydroxyphenyl)-propionic acid, 3-(3-hydroxyphenyl)-
propionic acid, and 4-hydroxycinnamic acid, which are
absorbed and excreted by urine [37] (Table 1).
Luteolin and its glycosides have been isolated from plants
used in traditional medicine to treat a wide range of dis-
eases. Tests for antiherpetic substances from crude methanol
leaf extract of Avicenna marina have shown that the most
active fraction isolated and analyzed contained luteolin 7-O-
methylether-3󸀠-O-beta-D-glucoside (LMEG). LMEG exerts
an inhibitory effect on the early stage of herpes simplex virus 2
(HSV-2) infection probably inhibitingHSV attachment to the
cell membrane and its entry into the cell [143]. Among several
compounds isolated from Swertia macrosperma, luteolin was
the most active compound in inhibiting the secretion of
hepatitis B virus surface antigen (HBsAg) and hepatitis
B virus e-antigen (HBeAg) with IC50 values of 0.02 and
0.02mM, respectively [144].
Regarding the antibacterial effects, luteolin is active
againstB. subtilis, S. aureus,P. fluorescens andE. coli [145, 146].
The major constituents isolated from the methanol extract
of Daucus carota (carrot) seeds are luteolin, luteolin-3󸀠-O-
beta-D-glucopyranoside, and luteolin-4󸀠-O-beta-D-glucopy-
ranoside. Both luteolin and its 4󸀠-O-glucoside demonstrated
bactericidal activity against S. aureus and E. coli (MIC =
5.0 × 10−2 and 1.0 × 10−1mg/mL, resp.) [147]. Luteolin shows
antibacterial and synergistic activity against amoxicillin-
resistant E. coli, acting via three mechanisms: inhibition of
proteins and peptidoglycan synthesis, inhibition of extended-
spectrum 𝛽-lactamases, and alteration of outer and inner
membrane permeability [148].
Luteolin and its glycosides also show antiparasitic activ-
ity. Luteolin present in extract from Melampyrum arvense
was the most active compound against Trypanosoma brucei
ssp. rhodesiense and L. donovani (IC(50) values 3.8 and
3.0 𝜇g/mL) [149]. Luteolin-7-O-𝛽-glucopyranoside displayed
the best antiplasmodial activity against P. falciparum (IC(50)
value 2.9 𝜇g/mL) [149].
2.7. Hydrolyzable Tannins. Hydrolyzable tannins are a class
of polyphenols that include gallotannins and ellagitannins
(ETs) (Figure 4). These compounds are present in fruits like
raspberry, cranberries, strawberries, walnuts, grapes, and
pomegranate. A main difference between these two groups
is that, upon gut microbial hydrolysis, gallotannins yield
glucose and gallic acid, whereas ellagitannins undergo lac-
tonization producing ellagic acid (Figure 4).
Ellagic acid is largely metabolized by the colon micro-
biota, giving rise to urolithin A (3,8-dihydroxy-6H-diben-
zopyran-6-one) and its monohydroxylated analog known as
urolithin B [150, 151].There is a large interindividual variation
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in the timing, quantity, and types of urolithins excreted in
urine by humans. These variations are due to the variations
in colonic microbiota composition [152, 153]. Despite all the
data indicating the microbial origin of urolithins, no specific
bacteria for urolithin biosynthesis have been yet identified.
One bacterium (Butyrivibrio spp.), responsible for ellagitan-
nins modification, has been identified in rumen fluids [38]
(Table 2).
Ellagic acid from Phyllanthus urinaria, a domestic plant
grown in Korea, shows specific antiviral activity against hep-
atitis B virus (HBV), by inhibiting HBeAg secretion, in HBV-
infected cells [154]. ETs are potent antiviral agents against
herpes simplex virus, specially eugenin extracted fromGeum
japonicum and Syzygium aromaticum [155]. Pomegranate
(Punica granatum) polyphenols suppress the replicative abil-
ity of influenza A virus in host cells. Punicalagin is the
most effective anti-influenza component in this extract,
blocking replication of influenza virus RNA and inhibiting
agglutination of chicken red blood cells by the virus [156, 157].
Geranin and corilagin are twoETs extracted fromPhyllanthus
amarus restrained by 50% the interaction of glycoprotein 120
of HIV-1 at concentrations from 2.65 to 0.48 𝜇g/mL on the
primary cellular receptor CD4 [158].
Plant extracts from Pteleopsis hylodendron, containing
mainly ellagic acid, are active against Klebsiella pneumoniae,
Bacillus cereus, E. coli, and S. typhi [159]. ETs present in
pomegranate peel are effective also in inhibiting S. aureus,
Salmonella, L. monocytogenes, and E. coli [160–164]. Ellagic
acid extract from pomegranate inhibits formation of biofilms
by S. aureus, methicillin resistant S. aureus (MRSA), and E.
coli. [79].
Punicalagin, punicalin, gallagic, and ellagic acids show
antifungal properties against Candida albicans, C. neofor-
mans, and Aspergillus fumigatus [165]. Apart from inhibiting
biofilm formation, pomegranate extracts disrupt preformed
biofilms and inhibited germ tube formation in C. albicans
[164].
In vitro antimalarial activity of ellagic acid has been
reported, with high in vitro activity against all P. falciparum
strains regardless of their levels of chloroquine and meflo-
quine resistance (50% inhibitory concentrations ranging
from 105 to 330 nM) [166]. This antimalarial activity takes
place at the mature trophozoite and young schizont stages,
corresponding to protein and nucleic acid synthesis. Ellagic
acid potentiates also the activity of current antimalarial drugs
such as chloroquine, mefloquine, artesunate, and atovaquone
[167].
2.8. Lignans. Lignans include a number of diphenolic com-
pounds with a 1,4-diarylbutane structure such as secoiso-
lariciresinol, matairesinol, pinoresinol, lariciresinol, isolari-
ciresinol, and syringaresinol. They are common in seeds as
flax and cereals and in fruits as strawberries and apricots.
Lignan metabolism involves both mammalian (glu-
curonidation and to a lesser degree sulfation) and gut
microbial processes [39]. Biological activity of lignans is
related to the activation of these compounds by Bacteroides
and Clostridium species (in the gut microbiota) to entero-
lactone and enterodiol (Figure 9), which are phytoestrogens
in mammals [40]. This transformation of lignans into phy-
toestrogens is carried out after demethylation and dehy-
droxylation reactions (carried out by Peptostreptococcus and
Eubacterium species), which increase the structural diversity
of enterolignan derivatives in blood circulation (Table 2) [41]
(Figure 9). Thus, enterolactone conversion from enterodiol
is a complex phenomenon, involving several precursors,
different intermediary metabolites, and diverse conjugation
patterns. Production of enterolactone was compared to that
of enterodiol and a ratio of enterolactone- and enterodiol-
converting bacteria of 1 : 2000 was observed, indicating that
enterodiol-producing bacteria are dominant in human gut
[42] (Table 2).
2.9. Chlorogenic Acids. Chlorogenic acids are a group of
compounds comprising hydroxycinnamates (such as caffeic
acid, ferulic acid, and p-coumaric acid) (Figure 1), linked
to a quinic acid to form a range of conjugated structures
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Table 2: Main metabolites derived from nonflavonoids and identified bacteria involved in their transformation.
Precursors Main identified metabolites Bacteria References
Ellagitannins Urolithins Butyrivibrio spp. [38]
Lignans EnterodiolEnterolactone
Bacteroides distasonis, Bacteroides fragilis, Bacteroides
ovatus, Clostridium cocleatum, Butyribacterium
methylotrophicum, Eubacterium callanderi,
Eubacterium limosum, Peptostreptococcus
productus, Clostridium scindens, Eggerthella lenta
[39–42]
Hydroxycinnamates
3-Hydroxyphenylpropionic acid
Benzoic acid
3-(4-Hydroxyphenyl)propionic acid
Vanillin
Escherichia coli, Bifidobacterium lactis, Lactobacillus
gasseri [43–45]
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Figure 9: Colonic formation of enterodiol and enterolactone from the lignan secoisolariciresinol diglucoside.
known, respectively, as caffeoylquinic acids, feruloylquinic
acids, and p-coumaroylquinic acids. They are abundant in
fruits as peaches and plums and in some seeds, like coffee.
Literature describing the bioavailability of chlorogenic
acids is scarce and contradictory. However, several micro-
bial metabolites have been identified. The main microbial
metabolites of caffeic acid are 3-hydroxyphenylpropionic
acid and benzoic acid, generated by the action of E. coli,
B. lactis, and Lactobacillus gasseri (Table 2). The first one
is formed by de-esterification, reduction of a double bond,
and dehydroxylation. Furthermore, 𝛽-oxidation shortens the
side-chain and forms benzoic acid in small degree. Both
metabolites are also obtained from chlorogenic acid [43].
The most frequent metabolites from ferulic acid produced
by colonic microbiota are vanillin and 3-(4-hydroxyphenyl)-
propionic acid [44, 45].
The antimicrobial activity of 22 polyphenols, including
gallic acid, was investigated against 26 bacterial species. It
was found that a structure-activity relationship between the
strongest antibacterial activity for those polyphenols and a
higher number of pyrogallol rings in their structure [168].
As gallic acid has one of those rings, its antibacterial activity
was classified by these authors as moderate. The role of gallic
acid is also of practical interest in the prevention of formation
of biofilms by different bacteria. When biofilms formed by
E. coli, P. aeruginosa, S. aureus, and L. monocytogenes were
studied, a reduction in biofilm activity >70% for all the
biofilms tested was found [169]. Gallic acid also inhibits
bacterial growth of Streptococcus mutants and the biofilm
formation in vitro and also influences the adhesion properties
of S. aureus [170].
Experimental evidences regarding the antiviral activity of
gallic acid have been published as the inhibition in human
rhinoviruses (HRVs), replication and reduction of HRV-
induced cytopathic effect in vitro, and antienterovirus 71
activity [171] were found. The same positive results of gallic
acid against herpes simplex virus type-2 were previously
mentioned [172].
Gallic acid purified from Terminalia nigrovenulosa bark
has shown strong antifungal activity against Fusarium solani
and strong nematicidal activity againstMeloidogyne incognita
[173, 174].
3. Conclusions
Most polyphenol nutraceuticals from plant origin must
undergo intestinal transformations, by microbiota and ente-
rocyte enzymes, in order to be absorbed at enterocyte and
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colonocyte levels. This gives rise to diverse beneficial effects
in the consumer, including a vast array of protective effects
against viruses, bacteria, and protozoan parasites. These
enzymatic transformations include elimination of glycosidic
tailoring by gut microbiota of diverse genera (Lactobacil-
lus, Eubacterium, and Bifidobacterium), as well as further
transformations in these aglycones’ level, giving rise to more
stable bioactive compounds that are incorporated into the
blood stream, as a vast array of benzoic acids, phenolic acids,
urolithins, and the phytoestrogens (S)-equol, enterodiol, and
enterolactone. In most cases, a complex network of different
intestinal microbiota species is necessary for full biotransfor-
mation, whereas earlier and simple reactions as deglycosyla-
tion can be carried out individually by specific gut strains.
The individual variability, at consumer level, with respect
to richness, and biodiversity of own intestinal microbiota
taxa are key determinants regarding the ability of a person
to get the most fully bioactive derivatives from ingested
polyphenols. Final absorbed bioactive derivatives have shown
antimicrobial properties against viruses (as HBV), Gram-
positive bacteria (as S. aureus, L. monocytogenes), and Gram-
negative bacteria (S. enterica, P. aeruginosa), but also against
eukaryote species as fungi (Candida spp., T. mentagrophytes)
or protozoans (T. cruzi, P. falciparum). Therefore, consump-
tion of food with high levels of polyphenols, together with
having appropriate gut microbiota diversity, is extremely
important, in order to help in the fight against infectious dis-
eases. Fermented dairy foods, as well as other ones with high
levels of beneficial microorganisms, can therefore contribute
to maintaining this appropriate gut microbiota diversity,
facilitating intestinal production of bioactive metabolites
from dietary polyphenols, as well as their absorption and
bioavailability.
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